BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Decrease in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) saw a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 2,800 shares, a drop of 80.1% from the October 15th total of 14,100 shares. Based on an average daily trading volume, of 91,400 shares, the days-to-cover ratio is presently 0.0 days.

BriaCell Therapeutics Price Performance

BCTXW stock opened at $0.27 on Thursday. BriaCell Therapeutics has a 12 month low of $0.11 and a 12 month high of $2.60. The firm’s fifty day simple moving average is $0.29 and its 200-day simple moving average is $0.35.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.